As I said they all but named biomarin in the investor day as an interested party. With CAP 51 naming them too, I have every expectation they are auctioning off a slice of the MPS pie with high sales price/low COG - BioMarin isn’t turning a profit.
Looking at the history of changes in 002 trial and the right range of dosing I think the FDA are quite convinced on efficacy in OA.
research reports and media, page-2399
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.010(4.65%) |
Mkt cap ! $78.73M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 23.5¢ | 21.5¢ | $288.5K | 1.279M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 130626 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 60000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |